p. 1−10
2676-6299
Vol.12/No.1
0.05). Doxycycline at 300 and 400 µg/ml significantly decreased FLSs viability (P<0.05). FLSs viability were 74.28% and 59.07% in 300 and 400 µg/ml, respectively, when measured by the MTT assay. Also FLSs viability at 300 and 400 µg/ml of doxycycline were 68.10% and 43.26%, respectively with Trypan blue exclusion method.Conclusion and Clinical Relevance- These findings demonstrate that doxycycline was not toxic for equine FLSs at concentration equal or less than 150 µg/ml in vitro. Further studies are needed to investigate the safety, efficacy and detrimental effects of doxycycline in equine joints.]]>
p. 11−17
2676-6299
Vol.12/No.1
p. 18−24
2676-6299
Vol.12/No.1
p. 25−32
2676-6299
Vol.12/No.1
p. 33−39
2676-6299
Vol.12/No.1
p. 40−48
2676-6299
Vol.12/No.1
p. 49−54
2676-6299
Vol.12/No.1
p. 55−63
2676-6299
Vol.12/No.1
p. 64−68
2676-6299
Vol.12/No.1
p. 69−73
2676-6299
Vol.12/No.1